Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10–17 years of age: Results from a randomised, controlled, double-blind trial.

Highlights: [•] We evaluated safety of an investigational HSV vaccine in girls aged 10–17 years. [•] Serious adverse events (SAEs) were evaluated over 12 months (primary objective). [•] SAE rates did not differ significantly between the HSV vaccine and control groups. [•] A clinically acceptable safety profile was observed for the HSV vaccine overall. [•] The HSV vaccine was immunogenic in this study group, regardless of HSV serostatus. [ABSTRACT FROM AUTHOR]